Appendix Mucinous Adenocarcinoma clinical trials at UC Health
1 in progress, 1 open to new patients
open to eligible people ages 18 years and up
This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
at UC IrvineUCSDUC Davis